BC-007 (Dragonboat Biopharmaceutical)

BC007（宝船生物）

Report date: 2022/08/16 11:06:44

Base Information

Drug NameBC-007 (Dragonboat Biopharmaceutical)
Drug Alias NameBC-007
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionClaudin-18 splice variant 2 antagonistsCluster of differentiation 47 inhibitors
TargetsClaudin-18 splice variant 2Cluster of differentiation 47
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesDragonboat Biopharmaceutical
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesDragonboat Biopharmaceutical
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A